Mesoblast (NASDAQ:MESO) received a $14.00 target price from analysts at Maxim Group in a report released on Wednesday, March 7th. The brokerage presently has a “buy” rating on the stock. Maxim Group’s price target points to a potential upside of 131.02% from the stock’s current price.
Several other equities research analysts have also issued reports on the stock. Zacks Investment Research raised shares of Mesoblast from a “hold” rating to a “buy” rating and set a $6.25 target price on the stock in a research note on Saturday, January 13th. Cantor Fitzgerald set a $23.00 price target on shares of Mesoblast and gave the company a “buy” rating in a research note on Wednesday, February 21st. Finally, Oppenheimer set a $16.00 price target on shares of Mesoblast and gave the company a “buy” rating in a research note on Wednesday, December 20th. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company’s stock. Mesoblast has a consensus rating of “Hold” and an average target price of $13.54.
Shares of Mesoblast stock opened at $6.06 on Wednesday. The firm has a market capitalization of $604.58, a PE ratio of -16.38 and a beta of 1.83. Mesoblast has a 12-month low of $4.74 and a 12-month high of $12.50.
An institutional investor recently bought a new position in Mesoblast stock. Penbrook Management LLC bought a new stake in Mesoblast limited (NASDAQ:MESO) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 266,800 shares of the company’s stock, valued at approximately $1,558,000. Mesoblast comprises about 1.4% of Penbrook Management LLC’s investment portfolio, making the stock its 18th largest position. Penbrook Management LLC owned about 0.28% of Mesoblast at the end of the most recent quarter. 2.85% of the stock is owned by institutional investors.
WARNING: This article was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/03/23/mesoblast-meso-given-a-14-00-price-target-by-maxim-group-analysts-2.html.
Mesoblast Company Profile
Mesoblast Limited is engaged in developing cell-based medicines. The Company has leveraged its technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a portfolio of late-stage product candidates. Its allogeneic, off-the-shelf cell product candidates target advanced stages of diseases with high, unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.